Original Articles Korean Circulation J 20003012 1530-1539 치료받지않은고혈압환자에서혈중단핵구 βark1 의 농도와좌심실질량의비교연구 최봉룡 1 김은지 2 이지은 3 윤지철 1 남중희 1 박성지 1 황진용 1 최동주 1 서봉관 1 Association between ARK1 Level of Circulating Mononuclear Leukocytes and Left Ventrcular Mass in Non-treated Hypertensive Patients Bong-Ryong Choi, MD 1, Eun-Ji Kim, BS 2, Ji-Eun Lee, BS 3, Ji-Cheol Yun, MD 1, Jung-Hee Nam, MD 1, Seong-Ji Park, MD 1, Jin-Yong Hwang, MD 1, Dong-Ju Choi, MD 1 and Bong-Gwan Seo, MD 1 1 Department of Interenal Medicine, Cardiovascular Research Center, 2 Pharmacology, 3 Neurobiology, College of Medicine, Gyeongsang National University, Kyungnam, Korea BackgroundBeta-adrenergic receptor Kinase 1 ARK1 is a serine/threonine kinase attached, which inhibits the coupling of -adrenergic receptor with G-protein. Myocardial ARK1 level is usually elevated in heart failure and hypertrophy, but it is not known whether the circulating ARK1 level is related with the degree of cardiac hypertrophy. This study was performed to evaluate the association of the ARK1 level in circulating mononuclear leukocytes MNL in untreated hypertension with left ventricular mass in hypertensive patients. MethodNineteen non-treated hypertensive patients were included for this study. High blood pressure was confirmed when systolic BP is over 150 mmhg or diastolic BP is over 95 mmhg. Echocardiography was performed to evaluate the degree of hypertrophy by measuring the left ventricular mass index LVMI and relative wall thickness RWT, and test the LV function by measuring the ejection fraction EF according to ASE guideline. At the same time, blood was collected from each patient and MNL were isolated by gradient centrifuge with Ficoll-400. Total RNA was purified from MNL and semi-quantitative RT-PCR was performed. After reverse transcription, PCR was done with primers for human ARK1 and GAPDH as external control. ARK1 levels were expressed by ratio to GAPDH level and estimated the relations with clinical and Echocardiographic parameters. ResultWe studied confirmed 19 hypertensive patients 10 men and 9 women, mean age of 50.6 years. Echocardiographically measured indices meansd were as followslvmi 137.3 30.6 g/m 2, PWT 0.530.09 and EF 54.68.5%. Ratio of ARK1 levels to GAPDH was from 0.10 to 0.96 0.620.25. ARK1 levels were correlated with LVMI correlation coefficientr0.502, p0.029 and RWT r0.627, p0.004. But Systolic BP r0.009, p0.93, diastolic BP r0.07, p0.85 or EF r0.045, p0.84 were not related to level of ARK1. ConclusionsThe ARK1 level of circulating MNL was correlated well with the degree of the cardiac hypertrophy estimated by LVMI and RWT. This data 1530
suggests that activation of sympatho-adrenal system would exert a major role in developing cardiac hypertrophy and we can expect the decreased responsiveness to catecholamine in the heart of hypertensive patients. ARK1 in circulating MNL might be used as a predictor or marker for LV hypertrophy in hypertensive patients. Korean Circulation J 2000;3012:1530-1539 KEY WORDSARK1 beta-adrenergic receptor Kinase 1 Hypertrophy LVMI Left Ventricular Mass Index. 서론 1531
대상및방법 대상 1532 방법 Fig. 1. Schematic diagram of M-mode of the left ventricle. The left ventricular interval dimension at enddiastole was measured at on set of the QRS complex and systolic S measurement was done at the maximal excursion of the ventricular septum. Interventricular septum and left ventricular posterior wall thickness were measured at the onset of the QRS complex. AbbreviationsST DVentricular septal thickness at enddiastole. LVD DLeft ventricular internal dimension at end-diastole. LVD SLeft ventricular internal dimension at end-systloe. PWT DLeft ventricular posterobasal free wall thickickness at end-diastole. Korean Circulation J 2000;3012:1530-1539
통계적방법 1533
임상양상 1534 결 Table 1. Clinical characteristics n19 Gender Men 10, Female 9 Age yr 50.4 12.3 Height cm 160.3 10.5 Body weight kg 62.4 14.5 Body surface area m 2 1.66 0.23 SBP mmhg Systolic 168.7 17.9 Diastolic 103.6 6.4 Heart rate /min 70.3 8.3 Values are meansd. 과 Table 2. Echocardiographic data n19 LVD S mm 31.4 3.5 LVD D mm 46.8 2.8 ST D mm 12.4 2.0 PWT D mm 12.4 1.8 RWT 0.53 0.1 LVEF % 54.6 8.5 LVM g 243.3 61.7 LVMI g/m 2 137.3 30.6 Values are meansd. LVD DLeft ventricular internal dimension at enddiastole LVD SLeft ventricular internal dimension at end-systloe ST DVentricular septal thickness at end-diastole PWT DLeft ventricular posterobasal free wall thickickness at end-diastole RWTRelative posterior wall thickickness LVEFLeft ventricular ejection fraction LVMLeft ventricular mass LVMILeft Ventricular mass index 심초음파상의지표 PCR cycle의결정 Fig. 2. Semiquantitative RT-PCR. Semiquantitative reverse transcriptase-polymerase chain reaction RT-PCR was perfomed to determine the adequate cycles for glyceraldehy-de-3-phosphate dehydrogenase GAD- PH and beta-adrenergic receptor kinase 1 ARK1. Fig. 3. Quantitation of PCR product. Proper polymerase chain reaction PCR cycle is determined as glyceraldehyde-3-phosphate dehydrogenase GAD- PH 30 cycle and beta-adrenergic receptor kinase 1 ARK1 33 cycle. Korean Circulation J 2000;3012:1530-1539
ARK1 GAPDH Fig. 4. RT-PCR sample of patients. After completion of PCR, each sample was run on the agarose gel and quantitated relative density of ARK1 compared with glyceraldehy-de-3-phosphate dehydrogenase GAPDH by SigmaGel with UV exposed photography. Ratio of ARK1 levels to GAPDH was from 0.10 to 0.96 0.620.25. Fig. 5. Correlation between ARK1 and LVMI. ARK1 beta-adrenergic receptor kinase 1. LVMIleft venticular mass index. βark1 발현의반정량분석 Fig. 6. Correlation between ARK1 and RWT. ARK1 beta-adrenergic receptor kinase 1. RWTrelative posterior wall thickensss. 고 찰 1535
Fig. 7. Correlation between ARK1 and BP. ARK1 beta-adrenergic receptor kinase 1. SBPsystolic pressure. DBPdiastolic pressure. Fig. 8. Correlation between ARK1 and EF. ARK1 beta-adrenergic receptor kinase 1. EFejection fraction. 1536 Korean Circulation J 2000;3012:1530-1539
- 요약 연구배경 : 1537
대상및방법 : 결과 : 결론 : 1538 중심단어 REFERENCES 1) Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relationof left ventricular and geometry to morbidity and mortality in men and women with essential hypertension. Ann Intern Med 1991114345-52. 2) Levy D, Garrison RJ, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham Heart Study. N Engl J Med 19903221561-6. 3) Casale PN, Deverreux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, et al. Value echocardiographic left ventrucular mass predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986105 173-8. 4) Kannel WB, Gordon G, Offut D. Left ventricular hypertrophy by electrocardiogrm prevalence, incidence, and mortality in the framingham study. Ann Intern Med 1969 7189-105. 5) Krzesinski JM, Rorive G, Van Cauwenberge H. Hypertension and left ventricular hypertrophy. Acta Cardiol 199651143-54. 6) Devereux RB, Alonso DR, Lamutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assesment of left ventricular hypertrophy Comparison to necropsy finding. Am J Cardiol 198657450-8. 7) HARVEST Study Group. Structural abnormalities and not diastolic dysfuction are the earliest left ventricular changes in hypertension. Am J Hypertension 199811 147-54. 8) Kim DI, Song JH, Im SW, Park SG, Chung EM, Cha DH, et al. Comparison of left ventricular hypertrophy between hypertensive and chronic renal disease patients. Korean J of Medicine 1998551005-21. 9) Verdechia G, Gatteschi C, Benemio F, Porcellati. Circar-dian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 199081 528-39. 10) Perloff D, Sokolow M. The prognostic value ambulatory blood pressure. JAMA 19832492792-8. 11) Kupari M, Koskinen P, Virolainen J. Correlates of left ventricular mass in a population sample aged 36 to 37 young focus on life style and salt intake. Circulation 1994891041-50. 12) Verdecchia P, Schillaci G, Borsioni C, Ciucci A, Zampi I, Battistelli M, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 1995 Oct131209-15. 13) de Simone G, Devereux RB, Mureddu GF, Roman MJ, Ganau A, Alderman MH, et al. Influence of obesity on left ventricular midwall mechanics in aterial hypertension. Hypertension 1996 Aug28276-83. Korean Circulation J 2000;3012:1530-1539
14) Libersonon PR, Grandits G, Prineas R, Dianzumba S, Flack JM, Cutler JA. Echocardiographic correlates of left ventricular structure amomg 844 mildly hypertensive men and women in the treatment of Mild Hypertensive study TOMHS. Circulation 199311905-18. 15) MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. N Engl J Med 1986314334-9. 16) Lindemann JP, Watanabe AM. Mechanisms of adrenergic and cholinergic regulation of myocardial contractility, Physiology and Pathophysiology of the Heart. Boston, Kluwer Academic Publisher, 19953467-94. 17) Ingles J, Freedman NJ, Koch WJ, Leflfowitz RJ. Structure and mechanism of G-protein-coupled receptor kinases. J Bio Chem 198326823735-8. 18) Ferguson SS, Barak LS, Zhang J, Caron MG. G-proteincoupled receptor regulation role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 1996 Oct741095-110. 19) Choi DJ, Koch W, Rockman H, Akhter RJ, Lefkowitz RJ. Level of ARK1 regulates myocardial contractilie function in gene targeted mice. Circulation 199796281-93. 20) Feldman AM, Bristow MR. The -adrenergic pathway in the failing human heart implications for inotrophic therapy. Cardiology 199077Suppl. 11-32. 21) Nozawa T, Igawa A, Yoshida N, Maeda M, Inoue M, Yamamura Y, et al. Dualtracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats. Circulation 1998 Jun 1697 2359-67. 22) Choi DJ, Koch WJ, Hunter JJ, Sockman HA. Mechanisms of -adrenergic receptor desensization in cardiac hypertrophy is increased -adrenergic receptor kinase. J Biol Chem 199727217223-9. 23) Gros RG, Benovic JL, Tan CM, Feldman RD. G- Protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 1997992087-93. 24) Sahn DJ, DeMaria A, Kisslo J, Weyman A. The committee on Mode standarization of the American Society of Echocardiography. Recommandations regarding quantation in M-mode echocardiography Results of survey of echocardiographic measure-ments. Circulation 197858 1072-83. 25) Devereux RB, Alonso DR, Lutas EM, Gottieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy comparision to necropsy finding. Am J Cardiol 198657450-8. 26) Dubois EF. Basal metabolism in Health and Disease. Philadelphia, La & Febiger1936. 27) Byum A. Isolation of mononuclear cell and granulocyte from human blood. Scan J Clin Lab Invest 196821suppl. 9777-89. 28) Naslund T, Silberstein DJ, Merrell WJ, Nadeau JH, Wood AJ. Low sodium intake corrects abnormality in beta-receptor-mediated arterial vasodilation in patients with hypertension correlation with beta-receptor function in vitro. Clin Pharmacol Ther 1990 Jul4887-95. 29) Feldman RD, Lawton WJ, McArdle WL. Low sodium diet corrects the defect in lymphocyte beta-adrenergic responsiveness in hypertensive subjects. J Clin Invest 1987 Jan79290-4. 30) Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ. Leukocyte beta-receptor alterations in hypertensive subjects. J Clin Invest 1984 Mar73648-53. 31) Brodde OE, Daul AE, O'Hara N, Khalifa AM. Properties of alpha-and beta-adrenoceptors in circulating blood cells ofpatients with essential hypertension. J Cardiovasc Pharmacol 19857Suppl 6S162-7. 32) Feldman RD, Tan CM, Chorazyczewski J. G protein alterations in hypertension and aging. Hypertension 1995 Nov26725-32. 33) Feldman RD. A low-sodium diet corrects the defect in beta-adrenergic response in older subjects. Circulation 1992 Feb85612-8. 34) Loudon RP, Perussia B, Benovic JL. Differentially regulated expression of the G-protein-coupled receptor kinases, betaark and GRK6, during myelomonocytic cell development in vitro. Blood 1996 Dec 15884547-57. 35) De Blasi A, Parruti G, Sallese M. Regulation of G proteincoupled receptor kinase subtypes in activated T lymphocytes. Selective increase of beta-adrenergic receptor kinase 1 and 2. J Clin Invest 1995 Jan95203-10. 36) Shasha SM, Shasha U, Kristal B, Barzilai M, Steinberger O, Shkolnik T. Proliferative response of T lymphocytes to mitogenic lectins in essential hypertension. Nephron 199158413-7. 37) Paietta E, Schwarzmeier JD. beta-adrenergic responsiveness of human peripheral lymphocytes after mitogenic transformation with phytohemagglutinin. Biochem Pharmacol. 1983 Oct 15323085-9. 38) Laxminarayana D, Kammer GM. Activation of type I protein kinase A during receptor-mediated human T lymphocyte activation. J Immunol 1996 Jan156497-506. 39) Kiuchi K, Shannon RP, Sato N, Bigaud M, Lajoie C, Morgan KG, et al. Factors involved in delaying the rise in peripheral resistance in developing heart failure. Am J Physiol 1994 Jul2671 Pt 2H211-6. 40) Colucci WS, Ribeiro JP, Rocco MB, Quigg RJ, Creager MA, Marsh JD, et al. Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization. Circulation 1989 Aug80314-23. 41) Maisel AS, Phillips C, Michel MC, Ziegler MG, Carter SM. Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure. Circulation. 1989 Sep80669-75. 42) Goldstein DS. Plasma norepinephrine in essential hypertension. A study of the studies. Hypertension 1981 Jan- Feb348-52. 43) Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in genetargeted mice. Proc Natl Acad Sci USA 1998 Jun957000-5. 1539